Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval

Leuk Lymphoma. 2014 Jan;55(1):195-7. doi: 10.3109/10428194.2013.789507. Epub 2013 Jun 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Drug Approval
  • Humans
  • Janus Kinases / antagonists & inhibitors
  • Primary Myelofibrosis / drug therapy*
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents
  • INCB018424
  • Pyrazoles
  • Janus Kinases